Clinical Trials
(MCLA-158)
Petosemtamab is being developed as a first line therapy for patients with PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). The LiGeR-HN1 trial is a phase 3, open-label, randomized trial comparing the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab.
More information is available at the clinicaltrials.gov website and the LiGeR trials website.
(MCLA-158)
Petosemtamab (MCLA-158) is being developed for the treatment of patients with incurable recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) who progressed on prior PD-1/PD-L1 and platinum chemotherapy. The LiGeR-HN2 trial is a phase 3 open-label, randomized trial comparing the efficacy and safety of petosemtamab vs. investigator’s choice of monotherapy treatment including cetuximab, methotrexate, or docetaxel.
More information is available at the clinicaltrials.gov website.
(MCLA-158)
Petosemtamab (MCLA-158) is being developed for the potential treatment of r/m HNSCC and other solid tumors. The evaluation of petosemtamab monotherapy in 2/3L r/m HNSCC, as well as petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC continues. The phase 2 trial of petosemtamab in combination with standard chemotherapy in 1L and 2L metastatic colorectal cancer (mCRC) and petosemtamab monotherapy in 3L+ mCRC is enrolling.
More information is available at the clinicaltrials.gov website.
MCLA-129 is currently being developed for the potential treatment of advanced non-small cell lung cancer (NSCLC) and other solid tumors. Our phase 1/2 trial is ongoing in the dose expansion phase of the open-label, multicenter trial. The evaluation of MCLA-129 monotherapy in METex14 NSCLC continues and the phase 2 trial of MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC is enrolling.
More information is available at the clinicaltrials.gov website.
Unless otherwise noted, we are providing this information as of February 27, 2025. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Merus’ most recent Annual Report on Form 10-K and in Merus’ other periodic reports on Form 10-Q and Form 8-K filed with the SEC, and actual results may vary materially. Merus provides this information as of the date above and does not undertake any obligation to update any forward-looking statements contained on these tables as a result of new information, future events or otherwise.
All Company therapeutic candidates described or mentioned herein are investigational and have not yet been approved for marketing by any regulatory authority.